OncLive TV

Alexander Olawaiye, MD, discusses the efficacy and safety of relacorilant plus nab-Paclitaxel in platinum-resistant ovarian cancer.

Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

Andrew Kuykendall, MD, discusses responses with rusfertide for patients with phlebotomy-dependent polycythemia vera.

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.

Thomas Powles, MD, MBBS, MRCP, shares data from an EFS subgroup analysis from the phase 3 CREST study in BCG-naive, high-risk NMIBC.

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.

Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.

Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin for the treatment of locally advanced or metastatic NSCLC with c-MET overexpression.

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.

Neelam Desai, MD, highlights the phase 3 PATINA study evaluating a palbociclib-based regimen in HR-positive/HER2-positive metastatic breast cancer.

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.

John M. Burke, MD, discusses the challenges associated with using venetoclax for CLL management across both community and academic oncology settings.

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.

Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Ryan T. Merrell, MD, discusses current treatment modalities for gliomas in recognition of Brain Tumor Awareness Month.